Skip to main content

Table 3 Data extracted from IQWiG publications [42]

From: Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies

No.

Identifier

Date

Endpoint

Page

Number of studies (k)

Effect measure

1

N15-06

2017-03

Morning pain

85

5

OR

2

N15-11

2017-03

Ear infection

62

2

OR

3

S15-02

2017-01

Mortality

53

2

OR

4

D15-02

2017-01

Mortality

74

2

OR

5

A16-71

2016-12

Morbidity

5

6

OR

6

A16-38

2016-12

Vomiting

4

2

RR

7

P14-03

2016-11

Breast cancer screening

55

3

RR

8

N14-02

2016-08

Remission from anxiety disorder

127

2

OR

9

A16-30

2016-08

AIDS-defining events

103

2

RR

10

N15-07

2016-08

Ejaculation dysfunction

89

4

OR

11

A16-11

2016-06

Serious adverse events

86

2

RR

12

A10-03

2016-04

Serious adverse events

89

2

OR

13

A15-57

2016-02

St. George’s respiratory questionnaire response

22

2

RR

14

A15-45

2016-01

Morbidity

24

2

OR

15

A15-31

2015-11

Mortality

87

2

RR

16

A15-25

2015-10

Serious adverse events

89

2

RR

17

A15-21

2015-07

Mortality

16

2

RR

18

S13-04

2015-05

Screening for abdominal aortic aneurysm

71

4

OR

19

A15-06

2015-05

Morbidity

96

3

RR

20

A15-05

2015-03

Morbidity

4

2

RR

21

A14-38

2015-01

Serious adverse events

65

3

RR

22

A14-25

2014-11

Serious adverse events

115

2

RR

23

A14-22

2014-10

Transition Dyspnea Index responder

67

2

RR

24

A14-19

2014-09

Urge to urinate

75

3

RR

25

A14-18

2014-09

Persistent virological response (SVR24)

194

3

RR

26

S13-03

2014-06

Participants with cervical intraepithelial neoplasia 3+

15

6

RR

27

A13-29

2013-10

Metformidosis

15

3

RR

28

A10-01

2013-08

Remissions

1183

2

OR

29

A13-20

2013-08

Visual acuity

28

3

RR

30

S11-01

2013-07

Bowel cancer

61

7

OR

31

A13-23

2013-06

Mortality

15

2

RR

32

A13-05

2013-04

Full recovery

19

4

RR

33

A05-10

2013-04

Cardiovascular death

75

3

RR

34

A12-19

2013-03

Ocular adverse event

17

2

RR

35

A05-18

2012-08

Serious adverse events

67

18

OR

36

A12-10

2012-07

Adverse events

20

3

RR

37

A12-03

2012-04

Loss of transplant

23

2

RR

38

A12-04

2012-04

Virus occurrence

22

3

RR

39

A09-05

2012-04

Alzheimer’s disease assessment scale

51

6

OR

40

A11-30

2012-03

Mortality

24

2

OR